

Table S1. Patient, lesions, and treatment characteristics of repeated courses of SBRT.

Characteristic		Value or Ndo. (%)
Total no. of patients		17
Total no. of metastases		46
Median age at start of SBRT (range)		68 (44-79)
Sex	Male	15 (88.2%)
	Female	2 (11.8%)
Performance Status	0	8 (47.1%)
	1	4 (23.5%)
	2	5 (29.4%)
Pack years	Not available	1 (5.9%)
	0	1 (5.9%)
	< 10	0
	10-20	4 (23.5%)
	> 20	11 (64.7%)
Primary tumour location	Hypopharynx	2 (11.8%)
	Larynx	4 (23.5%)
	Nasopharynx	2 (11.8%)
	Oral cavity	2 (11.8%)
	Oropharynx	7 (41.2%)
AJCC tumour classification (valid at the time of diagnosis)	T1	1 (5.9%)
	T2	6 (35.3%)
	T3	5 (29.4%)
	T4	5 (29.4%)
AJCC nodal classification (valid at the time of diagnosis)	N0	3 (17.6%)
	N1	3 (17.6%)
	N2	10 (58.8%)
	N3	1 (5.9%)
Primary treatment	Surgery	1 (5.9%)
	Surgery + RT	5 (29.4%)
	Surgery + RCHT	4 (23.5%)
	RCHT	7 (41.2%)
Metastasis timing	Metachronous	15 (88.2%)
	Synchronous	2 (11.8%)
Number of different SBRT	2	15 (88.2%)
	3	2 (11.8%)
Treated Lesions		46
	1 Lesions per SBRT	29 (63.1%)
	2 Lesions per SBRT	5 (=10) (21.7%)
	3 Lesions per SBRT	1 (=3) 6.5%)
	4 Lesions per SBRT	1 (=4) (8.7%)
Laterality	Left lower lobe	16 (15.5%)
	Left upper lobe	23 (22.3%)
	Right lower lobe	23 (22.3%)
	Right middle lobe	10 (9.7%)
	Right upper lobe	31 (30.1%)
Median clinical tumour volume, cm ³ (range)		3,21 (0.17; 49.62)

Dose, Gy/fraction number	60/10	14 (13.6%)
	48/6	20 (19.4%)
	45/3	69 (67%)
Adjuvant systemic therapy		
in total		6 (35.3%)
of which:		
CHT + ICI		2 (11.8%)
CHT + Cetuximab + ICI		1 (5.9%)
ICI alone		3 (17.6%)

RCHT: radiochemotherapy; RT: radiotherapy; ICI: immune checkpoint inhibitor; CHT: chemotherapy (various combinations of Cisplatin, Carboplatin, 5-FU, Docetaxel, and Methotrexat).